Company news
BioVaxys Technology Corp news in 2026
BioVaxys Technology Corp's news releases, calls and decks from 2026, newest first.
BioVaxys Technology Corp. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
September 8, 2026
BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer
May 1, 2026
BioVaxys Announces Phase I/II PESCO Trial Abstract Accepted for Presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2026
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
March 17, 2026
BioVaxys Announces Application for Management Cease Trade Order
March 3, 2026
BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
January 29, 2026
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)
January 20, 2026
BioVaxys 1Q2026 R&D and Collaborative Activity
January 15, 2026
BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer
January 8, 2026